"After more than a decade of planning, the launch of the African Medicines Agency (AMA) is being celebrated in Mombasa, Kenya, this week at the Seventh Biennial Scientific Conference on Medical Products Regulation in Africa. The agency's establishment marks a pivotal moment in Africa's public health, at a time when the need for biomedical research conducted in Africa, focused on African health problems, has never been greater."
"What's more, Africa's phenomenal population growth and pace of urbanization is bringing fresh challenges - as well as opportunities - around health and disease. In Africa's cities today, the inhabitants of increasingly affluent neighbourhoods are demanding high-quality medicines and health care. But in low-income areas, high population density, inadequate housing and poor sanitation are facilitating the spread of respiratory and diarrhoeal infections. And everywhere, inadequate diets, air pollution, smoking and physical inactivity are driving increased rates of cardiovascular disease, diabetes and cancer."
The African Medicines Agency (AMA) has launched, marking a pivotal moment for public health and Africa-focused biomedical research. Africa exhibits the highest human genetic diversity, which remains inadequately studied, leading to treatments and vaccines that can be less effective or harmful for some people of African ancestry. Recent cuts of billions in international funding have left millions without life-saving treatments and caused researcher and health-worker unemployment, exposing vulnerability from donor dependence. Rapid population growth and urbanization create mixed health challenges: affluent areas demand high-quality care while low-income areas face infectious disease spread and rising noncommunicable diseases. The AMA aims to strengthen regulatory capacity and advance Africa's role in biomedical research and health governance.
Read at Nature
Unable to calculate read time
Collection
[
|
...
]